|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | University of Utah |
|---|---|
| Collaborator: |
National Institutes of Health (NIH) |
| Information provided by: | University of Utah |
| ClinicalTrials.gov Identifier: | NCT00721864 |
Purpose
This study is designed to better understand the molecular biology of paroxysmal nocturnal hemoglobinuria (PNH) and to determine if prion protein (PrP) functions in long term hematopoietic stem cell renewal.
| Condition |
|---|
|
Hemoglobinuria, Paroxysmal |
| Study Type: | Observational |
| Study Design: | Cohort, Prospective |
| Official Title: | The Molecular Biology of Paroxysmal Nocturnal Hemoglobinuria (PNH) |
Whole Blood
| Estimated Enrollment: | 20 |
| Study Start Date: | May 2006 |
| Estimated Study Completion Date: | March 2012 |
| Estimated Primary Completion Date: | March 2012 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
|
Affected Population
Subjects suspected of having Paroxysmal Nocturnal Hemoglobinuria (PNH)
|
Paroxysmal nocturnal hemoglobinuria (PNH) is characterized by hemolytic anemia, thrombosis, and variable cytopenia. It can be associated with significant morbidity including acute kidney failure, cerebral infarction, mesenteric infarction, Budd-Chiari syndrome, aplastic anemia, and leukemic transformation. The average survival time from diagnosis is 15 years.
PNH is an acquired clonal disorder of the hematopoietic stem cell. Two distinct populations of hematopoietic cells exist in each PNH patient: one non-clonal population of normal cells, and one clonal population of PNH cells. The clonal population of PNH cells is identified by a mutation in the PIG-A gene that results in absence of the glycophosphatidylinositol (GPI) anchor of several surface proteins. Consequently, these surface proteins are unable to perform their functions on the cell surface. Deficiency of two of these surface proteins, CD55 (decay accelerating factor) and CD59 (membrane inhibitor of reactive lysis) that prevent complement mediated destruction, have been shown to underlie the clinical presentation of PNH. Identifying the mutation causing the predominant clones may help us better understand the molecular biology of PNH. When this is accomplished, new therapies to control and eventually cure the disease can be designed.
In addition, we propose to determine the function of PrP in human hematopoietic stem cells. PrP is a glycoprotein attached to the cell membrane by a glycosylphosphatidylinositol (GPI) anchor. In PNH, a disorder whose pathogenesis lies in the absence of GPI anchors, PrP expression is reduced in monocytes and granulocytes from the PNH clone.
Eligibility| Ages Eligible for Study: | 7 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Patients with paroxysmal nocturnal hemoglobinuria (PNH)
Inclusion Criteria:
Exclusion Criteria:
1. Those not meeting the inclusion criteria
Contacts and Locations| Contact: Josef T Prchal, MD | 801-581-4220 | josef.prchal@hsc.utah.edu |
| Contact: Kim Hickman, BS | 801-581-3707 | kimberly.hickman@hsc.utah.edu |
| United States, Utah | |
| University of Utah | Recruiting |
| Salt Lake City, Utah, United States, 84132 | |
| Contact: Josef T Prchal, MD 801-581-4220 josef.prchal@hsc.utah.edu | |
| Contact: Kim Hickman, BS 801-581-3707 kimberly.hickman@hsc.utah.edu | |
| Principal Investigator: Josef T Prchal, MD | |
| Sub-Investigator: Charles Parker, MD | |
| Principal Investigator: | Josef T Prchal, MD | University of Utah |
More Information
| Responsible Party: | University of Utah ( Josef T. Prchal, MD ) |
| Study ID Numbers: | 17790, R01HL5077-12 |
| Study First Received: | July 23, 2008 |
| Last Updated: | October 8, 2009 |
| ClinicalTrials.gov Identifier: | NCT00721864 History of Changes |
| Health Authority: | United States: Institutional Review Board |
|
Paroxysmal Nocturnal Hemoglobinuria PIG-A Mutation Prion Protein Hematopoietic stem cells Clonal disorder |
|
Signs and Symptoms Urological Manifestations Hemoglobinuria Proteinuria Urologic Diseases Hematologic Diseases |
Urination Disorders Myelodysplastic Syndromes Anemia Hemoglobinuria, Paroxysmal Anemia, Hemolytic Bone Marrow Diseases |